BioCardia, Inc. (BCDA)
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases.
Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease.
The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.
In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths.
The company is based in San Carlos, California.
125 Shoreway Rd Ste B
San Carlos, California 94070-2718
|Phone||650 226 0120|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Peter A. Altman||Chief Executive Officer, President and Director|
|David McClung||Chief Financial Officer|
|Dr. Ian McNiece Ph.D.||Chief Scientific Officer|
|Edward M. Gillis||Senior Vice President of Devices|
|Dr. Sujith Shetty||Chief Medical Officer and Vice President of Clinical and Regulatory|
Latest SEC Filings
|Dec 15, 2021||8-K||Current report|
|Nov 18, 2021||4||Statement of changes in beneficial ownership of securities|
|Nov 10, 2021||8-K||Current report|
|Nov 10, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Oct 21, 2021||8-K||Current report|
|Oct 12, 2021||8-K||Current report|
|Oct 7, 2021||8-K||Current report|
|Sep 22, 2021||SC 13D||General statement of acquisition of beneficial ownership|
|Sep 10, 2021||8-K||Current report|
|Aug 18, 2021||4||Statement of changes in beneficial ownership of securities|
|View All SEC Filings|